Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer

NCT01198535 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

60

Enrollment

NIH

Sponsor class

Conditions

Colon Mucinous Adenocarcinoma
Colon Signet Ring Cell Adenocarcinoma
Rectal Mucinous Adenocarcinoma
Rectal Signet Ring Cell Adenocarcinoma
Recurrent Colon Carcinoma
Recurrent Rectal Carcinoma
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer

Interventions

BIOLOGICAL: Cetuximab
DRUG: Gamma-Secretase Inhibitor RO4929097
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)